These innovative molecules represent a significant advancement in the treatment of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in controlling blood glucose https://katrinajkjz729767.vblogetin.com/45136387/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide